PK/PD profiles of mTOR inhibitors in older adults
Official title: Pharmacokinetics (PK) and Pharmacodynamics (PD) Characterization of mTOR Inhibitors in Older Adults
Funded at Ut Southwestern Medical Center · NIH-11402672 · Data updated 2026-11-12
This grant studies how two mTOR drugs behave in the bodies of people aged 65 and up to help design safer, more effective aging-related therapies.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ut Southwestern Medical Center NIH-funded |
| Lab location | 1 site (Dallas, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $611,167 |
| NIH project number | 5U01AG081450-03 |
| Project ID | NIH-11402672 on NIH RePORTER |
Who could benefit from this research
✓Could help
Older adults (typically 65+) without significant confounding illnesses who may participate in PK/PD testing.
✕Less likely to help
Individuals with complex health issues or contraindications to mTOR inhibitors may not benefit and could be excluded for safety.
What this research studies
Researchers will measure how sirolimus and everolimus move through and affect the bodies of older adults without major illnesses. The work includes validating how we measure drug levels and biological markers that show aging-related changes, so future trials can be designed with clear expectations. A multidisciplinary team from geriatrics, pharmacology, and epidemiology will collect data and analyze pharmacokinetic and pharmacodynamic parameters to minimize confounding factors. The findings aim to provide reliable PK/PD data and biomarkers that could guide later clinical studies in aging-related interventions.
Why it matters
Potential benefit: If successful, the study could lead to better dosing guidelines and biomarkers for aging-related therapies in older adults.
How similar studies have gone: Previous studies show age can alter drug pharmacokinetics, but specific PK/PD data for sirolimus and everolimus in healthy older adults are limited, making this trial important and relatively novel.
Where this research is happening
-
Ut Southwestern Medical Center
Dallas, United States Active
Researchers
- Principal investigator: Timofte, Irina — Ut Southwestern Medical Center
- Study coordinator: Timofte, Irina
Related research
Other NIH-funded projects on the same topics.
-
Sub-second acetylcholine release in the brain for Alzheimer’s dementia
A small, quick stimulations-based study aims to boost a brain chemical called acetylcholine to help people with Alzheimer’s disease by using a targeted brain stimulation approach.
-
Understanding how broadly neutralizing antibodies may help HIV cure trials
A study at UC San Francisco looks at how antibody medicines behave in people on and off HIV therapy to help design better cure strategies.
-
Improving HIV-related brain infections by studying how drugs reach the brain
This grant looks at how well drugs reach the brain and spine to treat HIV-related infections like cryptococcal meningitis and TB meningitis in people with AIDS.
-
Transdermal delivery patch for zanamivir to treat influenza in patients
A new skin patch delivers zanamivir to people with flu or at risk of flu, aiming for easier, safer treatment than pills.
-
Chesapeake-Ohio Pharmacokinetics Core supports cancer drug testing
A collaborative core lab helps researchers study how cancer drugs behave in the body to improve clinical trials and patient care.
-
Urine color test to check tuberculosis drug levels in children and adults
This project uses a simple urine color test to see whether children and adults with TB are getting enough of key TB medicines like rifampin.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.